Rosanna Squitti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5088172/publications.pdf

Version: 2024-02-01

66234 98622 5,486 133 42 67 citations h-index g-index papers 137 137 137 5995 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: A meta-analysis. Neurobiology of Disease, 2013, 59, 100-110.	2.1	260
2	Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiology of Aging, 2014, 35, S74-S78.	1.5	251
3	Copper and Zinc Dysregulation in Alzheimer's Disease. Trends in Pharmacological Sciences, 2018, 39, 1049-1063.	4.0	188
4	Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF Â-amyloid, and h-tau. Neurology, 2006, 67, 76-82.	1.5	176
5	Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology, 2005, 64, 1040-1046.	1.5	158
6	Role of Copper in the Onset of Alzheimer's Disease Compared to Other Metals. Frontiers in Aging Neuroscience, 2017, 9, 446.	1.7	141
7	Copper in Alzheimer's Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal Fluid Studies. Journal of Alzheimer's Disease, 2012, 30, 981-984.	1.2	130
8	Longitudinal prognostic value of serum "free―copper in patients with Alzheimer disease. Neurology, 2009, 72, 50-55.	1.5	129
9	Zinc and COVID-19: Basis of Current Clinical Trials. Biological Trace Element Research, 2021, 199, 2882-2892.	1.9	114
10	Copper in Alzheimer's Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal Fluid Studies. Journal of Alzheimer's Disease, 2011, 24, 175-185.	1.2	109
11	Copper in tumors and the use of copper-based compounds in cancer treatment. Journal of Inorganic Biochemistry, 2022, 226, 111634.	1.5	109
12	Meta-Analysis of Serum Non-Ceruloplasmin Copper in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 809-822.	1.2	101
13	Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease. Annals of Neurology, 2014, 75, 574-580.	2.8	93
14	Apolipoprotein E and alpha brain rhythms in mild cognitive impairment: A multicentric Electroencephalogram study. Annals of Neurology, 2006, 59, 323-334.	2.8	92
15	Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clinical Neurophysiology, 2010, 121, 502-507.	0.7	84
16	â€~Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. Journal of Neural Transmission, 2007, 114, 1589-1594.	1.4	82
17	Low-copper diet as a preventive strategy for Alzheimer's disease. Neurobiology of Aging, 2014, 35, S40-S50.	1.5	81
18	Ceruloplasmin/Transferrin System Is Related to Clinical Status in Acute Stroke. Stroke, 2009, 40, 1282-1288.	1.0	79

#	Article	IF	Citations
19	Genotype (cystatin C) and EEG phenotype in Alzheimer disease and mild cognitive impairment: A multicentric study. Neurolmage, 2006, 29, 948-964.	2.1	76
20	Zinc in Alzheimer's Disease: AÂMeta-Analysis of Serum, Plasma, andÂCerebrospinal Fluid Studies. Journal of Alzheimer's Disease, 2015, 46, 75-87.	1.2	75
21	Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. Neurobiology of Disease, 2005, 18, 638-648.	2.1	73
22	Metals in alzheimer's disease: a systemic perspective. Frontiers in Bioscience - Landmark, 2012, 17, 451.	3.0	73
23	Copper dyshomeostasis in Wilson disease and Alzheimer's disease as shown by serum and urine copper indicators. Journal of Trace Elements in Medicine and Biology, 2018, 45, 181-188.	1.5	73
24	Free Copper Distinguishes Mild Cognitive Impairment Subjects from Healthy Elderly Individuals. Journal of Alzheimer's Disease, 2011, 23, 239-248.	1.2	72
25	Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. BioMetals, 2008, 21, 367-372.	1.8	66
26	Copper imbalance in Alzheimer's disease: Convergence of the chemistry and the clinic. Coordination Chemistry Reviews, 2019, 397, 168-187.	9.5	65
27	Towards a Unified Vision of Copper Involvement in Alzheimer's Disease: A Review Connecting Basic, Experimental, and Clinical Research. Journal of Alzheimer's Disease, 2015, 44, 343-354.	1.2	64
28	Fe and Cu do not differ in Parkinson's disease: A replication study plus meta-analysis. Neurobiology of Aging, 2013, 34, 632-633.	1.5	62
29	ATP7B Variants as Modulators of Copper Dyshomeostasis in Alzheimer's Disease. NeuroMolecular Medicine, 2013, 15, 515-522.	1.8	60
30	Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer's disease subjects. Clinical Neurophysiology, 2007, 118, 1244-1260.	0.7	58
31	Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1633-1641.	1.5	57
32	Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer disease. Prion, 2008, 2, 23-27.	0.9	55
33	Copper dysfunction in Alzheimer's disease: From meta-analysis of biochemical studies to new insight into genetics. Journal of Trace Elements in Medicine and Biology, 2012, 26, 93-96.	1.5	54
34	Atypical dementia associated with a novel presenilin-2 mutation. Annals of Neurology, 2003, 54, 832-836.	2.8	51
35	Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 1181-1189.	1.2	51
36	Association of K832R and R952K SNPs of Wilson's Disease Gene with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 913-919.	1.2	50

#	Article	IF	CITATIONS
37	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. Neuroscience Letters, 2004, 356, 119-122.	1.0	49
38	Linkage Disequilibrium and Haplotype Analysis of the <i>ATP7B </i> Gene in Alzheimer's Disease. Rejuvenation Research, 2013, 16, 3-10.	0.9	48
39	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. Trials, 2012, 13, 73.	0.7	47
40	Hyperhomocysteinemia, intima-media thickness and C677T MTHFR gene polymorphism: A correlation study in patients with cognitive impairment. Atherosclerosis, 2009, 206, 309-313.	0.4	46
41	Levels of Serum Ceruloplasmin Associate With Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 370-375.	0.9	45
42	Copper imbalance in Alzheimer's disease: Overview of the exchangeable copper component in plasma and the intriguing role albumin plays. Coordination Chemistry Reviews, 2018, 371, 86-95.	9.5	44
43	Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by d-penicillamine. Neuroscience Letters, 2002, 329, 137-140.	1.0	43
44	Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiology of Aging, 2005, 26, 455-464.	1.5	43
45	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiology of Aging, 2013, 34, 1711.e7-1711.e13.	1.5	43
46	Non-Ceruloplasmin Copper Distincts Subtypes in Alzheimer's Disease: a Genetic Study of ATP7B Frequency. Molecular Neurobiology, 2017, 54, 671-681.	1.9	40
47	Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability. Frontiers in Neuroscience, 2019, 13, 86.	1.4	40
48	An observational study on the influence of the APOE-ε4 allele on the correlation between †free†copper toxicosis and EEG activity in Alzheimer disease. Brain Research, 2008, 1215, 183-189.	1.1	39
49	Neuronal functionality assessed by magnetoencephalography is related to oxidative stress system in acute ischemic stroke. NeuroImage, 2009, 44, 1267-1273.	2.1	39
50	Copper subtype of Alzheimer's disease (AD): Meta-analyses, genetic studies and predictive value of non-ceruloplasmim copper in mild cognitive impairment conversion to full AD. Journal of Trace Elements in Medicine and Biology, 2014, 28, 482-485.	1.5	39
51	Non-ceruloplasmin bound copper and ATP7B gene variants in Alzheimer's disease. Metallomics, 2016, 8, 863-873.	1.0	39
52	Implications of metal exposure and liver function in Parkinsonian patients resident in the vicinities of ferroalloy plants. Journal of Neural Transmission, 2009, 116, 1281-1287.	1.4	37
53	Agents Complexing Copper as a Therapeutic Strategy for the Treatment of Alzheimers Disease. Current Alzheimer Research, 2009, 6, 476-487.	0.7	36
54	Diabetes and Alzheimer's Disease: Can Elevated Free Copper Predict the Risk of the Disease?. Journal of Alzheimer's Disease, 2017, 56, 1055-1064.	1.2	36

#	Article	IF	CITATIONS
55	Oxidative stress and brain glutamate-mediated excitability in depressed patients. Journal of Affective Disorders, 2010, 127, 321-325.	2.0	35
56	Ceruloplasmin/Transferrin Ratio Changes in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	1.1	35
57	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 30, 745-749.	1.2	35
58	Copper Hypothesis in the Missing Hereditability of Sporadic Alzheimer's Disease: ATP7B Gene as Potential Harbor of Rare Variants. Journal of Alzheimer's Disease, 2012, 29, 493-501.	1.2	34
59	Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy. Journal of Neural Transmission, 2014, 121, 1281-1286.	1.4	34
60	GSTM1 null genotype as risk factor for late-onset Alzheimer's disease in Italian patients. Journal of the Neurological Sciences, 2012, 317, 137-140.	0.3	33
61	Measurements of serum non-ceruloplasmin copper by a direct fluorescent method specific to Cu(II). Clinical Chemistry and Laboratory Medicine, 2017, 55, 1360-1367.	1.4	33
62	Agricultural Use of Copper and Its Link to Alzheimer's Disease. Biomolecules, 2020, 10, 897.	1.8	33
63	Copper Imbalance in Alzheimer's Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating ATP7B Gene Variants. Biomolecules, 2021, 11, 960.	1.8	33
64	GSTO1*E155del polymorphism associated with increased risk for late-onset Alzheimer's disease: Association hypothesis for an uncommon genetic variant. Neuroscience Letters, 2012, 506, 203-207.	1.0	32
65	Inflammation and iron metabolism in adult patients with epilepsy: Does a link exist?. Epilepsy Research, 2013, 107, 244-252.	0.8	32
66	Neurodevelopmental disorders: Metallomics studies for the identification of potential biomarkers associated to diagnosis and treatment. Journal of Trace Elements in Medicine and Biology, 2020, 60, 126499.	1.5	32
67	Copper Imbalance in Alzheimer's Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology. Journal of Alzheimer's Disease, 2021, 83, 23-41.	1.2	31
68	Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases. Frontiers in Aging Neuroscience, 2013, 5, 37.	1.7	30
69	Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	1.1	29
70	Functional and structural balances of homologous sensorimotor regions in multiple sclerosis fatigue. Journal of Neurology, 2015, 262, 614-622.	1.8	29
71	Copper Perturbation in 2 Monozygotic Twins Discordant for Degree of Cognitive Impairment. Archives of Neurology, 2004, 61, 738.	4.9	28
72	Metal-Score as a Potential Non-Invasive Diagnostic Test for Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 191-198.	0.7	28

#	Article	IF	Citations
73	Novel T719P A \hat{l}^2 PP Mutation Unbalances the Relative Proportion of Amyloid- \hat{l}^2 Peptides. Journal of Alzheimer's Disease, 2009, 18, 295-303.	1.2	27
74	Serum copper profile in patients with type 1 diabetes in comparison to other metals. Journal of Trace Elements in Medicine and Biology, 2019, 56, 156-161.	1.5	25
75	Intronic rs2147363 Variant in ATP7B Transcription Factor-Binding Site Associated with Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 453-459.	1.2	24
76	Non-Ceruloplasmin Copper Distinguishes A Distinct Subtype of Alzheimer's Disease: A Study of EEG-Derived Brain Activity. Current Alzheimer Research, 2016, 13, 1374-1384.	0.7	24
77	Copper phenotype in Alzheimer's disease: dissecting the pathway. American Journal of Neurodegenerative Disease, 2013, 2, 46-56.	0.1	24
78	Commentary: The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease. Frontiers in Neurology, 2017, 8, 503.	1.1	22
79	Zinc Therapy in Early Alzheimer's Disease: Safety and Potential Therapeutic Efficacy. Biomolecules, 2020, 10, 1164.	1.8	22
80	Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study. Current Alzheimer Research, 2017, 14, 1318-1326.	0.7	22
81	Evaluation of zinc, copper, and Cu:Zn ratio in serum, and their implications in the course of COVID-19. Journal of Trace Elements in Medicine and Biology, 2022, 71, 126944.	1.5	22
82	In silico investigation of the ATP7B gene: insights from functional prediction of non-synonymous substitution to protein structure. BioMetals, 2014, 27, 53-64.	1.8	21
83	Association between sex, systemic iron variation and probability of Parkinson's disease. International Journal of Neuroscience, 2016, 126, 354-360.	0.8	19
84	Cortical excitability and rest activity properties in patients with depression. Journal of Psychiatry and Neuroscience, 2007, 32, 259-66.	1.4	19
85	Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers. Journal of Alzheimer's Disease, 2018, 62, 1507-1518.	1.2	18
86	Plasma Extracellular Vesicle Size and Concentration Are Altered in Alzheimer's Disease, Dementia With Lewy Bodies, and Frontotemporal Dementia. Frontiers in Cell and Developmental Biology, 2021, 9, 667369.	1.8	18
87	Antioxidant Status and APOE Genotype As Susceptibility Factors for Neurodegeneration in Alzheimer's Disease and Vascular Dementia. Rejuvenation Research, 2013, 16, 51-56.	0.9	17
88	Biological factors and age-dependence of primary motor cortex experimental plasticity. Neurological Sciences, 2016, 37, 211-218.	0.9	17
89	Anti-Copper Therapies in Alzheimers Disease: New Concepts. Recent Patents on CNS Drug Discovery, 2009, 4, 209-219.	0.9	17
90	Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients. Biomarker Insights, 2007, 1, 205-13.	1.0	17

#	Article	IF	CITATIONS
91	Single nucleotide polymorphisms in the human <i>ATP7B</i> gene modify the properties of the ATP7B protein. Metallomics, 2019, 11, 1128-1139.	1.0	15
92	Copper in Glucose Intolerance, Cognitive Decline, and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2019, 33, 77-85.	0.6	15
93	Nerve Growth Factor-Based Therapy in Alzheimer's Disease and Age-Related Macular Degeneration. Frontiers in Neuroscience, 2021, 15, 735928.	1.4	15
94	Copper Status Abnormalities and How to Measure Them in Neurodegenerative Disorders. Recent Patents on CNS Drug Discovery, 2010, 5, 182-194.	0.9	13
95	An exploratory study of BDNF and oxidative stress marker alterations in subacute and chronic stroke patients affected by neuropathic pain. Journal of Neural Transmission, 2017, 124, 1557-1566.	1.4	13
96	No association between Ala9Val functional polymorphism of MnSOD gene and schizophrenia in a representative Italian sample. Neuroscience Letters, 2006, 410, 208-211.	1.0	12
97	Prognostic Value of Serum Copper for Post-Stroke Clinical Recovery: A Pilot Study. Frontiers in Neurology, 2018, 9, 333.	1.1	12
98	Microglia and Astrocytes in Alzheimer's Disease in the Context of the Aberrant Copper Homeostasis Hypothesis. Biomolecules, 2021, 11, 1598.	1.8	12
99	Meta-Analysis Study on the Role of Bone-Derived Neurotrophic Factor Val66Met Polymorphism in Parkinson's Disease. Rejuvenation Research, 2015, 18, 40-47.	0.9	11
100	Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy. Metabolic Brain Disease, 2015, 30, 1445-1452.	1.4	11
101	Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis. Results in Chemistry, 2021, 3, 100148.	0.9	11
102	Movement disorders and brain iron overload in a new subtype of aceruloplasminemia. Parkinsonism and Related Disorders, 2015, 21, 658-660.	1.1	10
103	Lack of association between MnSOD gene polymorphism and sporadic Alzheimer's Disease. Aging Clinical and Experimental Research, 2005, 17, 445-448.	1.4	9
104	Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients. Biomarker Insights, 2006, 1, 117727190600100.	1.0	9
105	Glutamate-Mediated Primary Somatosensory Cortex Excitability Correlated with Circulating Copper and Ceruloplasmin. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	1.1	9
106	Sensorimotor Cortex Reorganization in Alzheimer's Disease and Metal Dysfunction: A MEG Study. International Journal of Alzheimer's Disease, 2013, 2013, 1-8.	1.1	9
107	The Role of Copper in Human Diet and Risk of Dementia. Current Nutrition Reports, 2015, 4, 114-125.	2.1	8
108	Structural effects of stabilization and complexation of a zinc-deficient superoxide dismutase. Heliyon, 2021, 7, e06100.	1.4	8

#	Article	IF	Citations
109	Alzheimer's Disease and Retinal Degeneration: A Glimpse at Essential Trace Metals in Ocular Fluids and Tissues. Current Alzheimer Research, 2020, 16, 1073-1083.	0.7	8
110	Non-Ceruloplasmin Copper as a Stratification Biomarker of Alzheimer's Disease Patients: How to Measure and Use It. Current Alzheimer Research, 2021, 18, 533-545.	0.7	8
111	Serum Copper is not Altered in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 63, 1427-1432.	1.2	6
112	A comparison between radiometric and fluorimetric methods for measuring SSAO activity. Journal of Neural Transmission, 2013, 120, 1015-1018.	1.4	5
113	Polymorphic Genetic Markers of the GABA Catabolism Pathway in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 301-311.	1.2	5
114	Copper Status in Alzheimer's Disease and Other Neurodegenerative Disorders 2013. International Journal of Alzheimer's Disease, 2013, 2013, 1-2.	1.1	4
115	Duplication of FOXP2 binding sites within CNTNAP2 gene in a girl with neurodevelopmental delay. Minerva Pediatrics, 2017, 69, 162-164.	0.2	4
116	The Rise in Cytoplasmic Ubiquitin Levels Is an Early Step in the Response of Parasympathetic Ganglionic Neurons to Axonal Injury Followed by Regeneration. Journal of Neuropathology and Experimental Neurology, 1998, 57, 1000-1012.	0.9	3
117	Copper involvement in glutamatergic transmission in physiology and disease as revealed by magnetoencephalography/electroencephalography (MEG/EEG) studies. Aging Clinical and Experimental Research, 2019, 33, 2023-2026.	1.4	3
118	Iron Serum Markers Profile in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 78, 1373-1380.	1.2	3
119	Molecular mechanisms underlying copper function and toxicity in neurons and their possible therapeutic exploitation for Alzheimer's disease. Aging Clinical and Experimental Research, 2021, 33, 2027-2030.	1.4	3
120	Metal Dysfunction in Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 73-97.	0.4	3
121	Regulatory miRNAs in Cardiovascular and Alzheimer's Disease: A Focus on Copper. International Journal of Molecular Sciences, 2022, 23, 3327.	1.8	3
122	Copper Status in Alzheimer's Disease and Other Neurodegenerative Disorders: Genetics, Mechanisms, Neurophysiology, and Therapies. International Journal of Alzheimer's Disease, 2011, 2011, 1-2.	1.1	2
123	Explorative genetic association study of <i>GSTT2B</i> copy number variant in complex disease risks. Annals of Human Biology, 2016, 43, 279-284.	0.4	2
124	Metals Involvement in Alzheimer's Disease — A Patho-Genetic View. , 2015, , .		1
125	Copper in Alzheimer's Disease. , 2017, , 19-34.		1
126	Multi-modal factors for recovery prognosis in acute stroke. Aging Clinical and Experimental Research, 2019, 33, 1717-1719.	1.4	1

#	Article	IF	CITATIONS
127	ATP7B and Alzheimer Disease. , 2019, , 427-436.		1
128	P4-064: NON-CERULOPLASMIN COPPER AS A RISK FOR ALZHEIMER'S DISEASE: VALUE OF SERUM NON-CERULOPLASMIN COPPER FOR PREDICTION OF MCI CONVERSION TO AD-META-ANALYTIC AND GENETIC EVIDENCE OF COPPER DYSFUNCTION IN AD. , 2014, 10, P806-P806.		0
129	Copper Subtype of Alzheimer Disease: A Genetic Study of ATP7B Frequency. American Journal of Clinical Pathology, 2015, 144, A242-A242.	0.4	0
130	Antioxidant Status in Vascular Dementia. , 2015, , 529-537.		0
131	20 Value of Serum Oxidative Stress and Metal Profiling for Post-Stroke Functional Recovery. American Journal of Clinical Pathology, 2018, 149, S8-S9.	0.4	0
132	26 Copper Failure in Wilson and Alzheimer Disease. American Journal of Clinical Pathology, 2018, 149, S11-S11.	0.4	0
133	333 Genetic Screening of Cystic Fibrosis Transmembrane Regulator (CFTR) in 3,746 Infertile Candidate Couples for Assisted Reproductive Techniques. American Journal of Clinical Pathology, 2018, 149, S143-S144.	0.4	0